[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:hunter-syndrome":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":68,"states":69},"Hunter Syndrome",9,6,[8,16,23,29,35,41,47,55,61],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05371613","A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)",[12],"Phase 2\u002FPhase 3","RECRUITING","2026-08-26T02:19:27.519777Z","2026-05-05T02:35:31.902266Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04532047","PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)",[20],"Phase 1","2026-08-26T02:16:56.877406Z","2026-05-05T02:43:29.333359Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT02254863","UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells",[20],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:26.720663Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05619900","Registry of Patients Diagnosed With Lysosomal Storage Diseases",[],"2026-08-26T02:15:47.754948Z","2026-05-13T02:55:06.364859Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT04528355","Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC",[],"2026-08-26T02:16:24.970704Z","2026-05-13T02:55:06.255132Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT03333200","Longitudinal Study of Neurodegenerative Disorders",[],"2026-08-26T02:18:51.009190Z","2026-05-13T02:55:06.121889Z",{"nct_id":48,"title":49,"phases":50,"status":52,"updated_at":53,"content_modified":54},"NCT05594992","An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects",[51],"Phase 3","ENROLLING_BY_INVITATION","2026-08-26T02:17:34.833510Z","2026-06-16T05:54:08.044374Z",{"nct_id":56,"title":57,"phases":58,"status":52,"updated_at":59,"content_modified":60},"NCT05368038","ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program",[],"2026-08-26T02:18:52.966503Z","2026-06-16T05:54:08.030731Z",{"nct_id":62,"title":63,"phases":64,"status":65,"updated_at":66,"content_modified":67},"NCT03655223","Early Check: Expanded Screening in Newborns",[],"ACTIVE_NOT_RECRUITING","2026-08-03T03:53:57.297126Z","2026-06-16T05:54:07.977837Z",[],[70,74,77],{"state":71,"count":72,"slug":73},"California",4,"california",{"state":75,"count":72,"slug":76},"Pennsylvania","pennsylvania",{"state":78,"count":79,"slug":80},"North Carolina",3,"north-carolina"]